8-K: Cue Biopharma Announces Positive Phase 1 Trial Data and Third Quarter 2024 Financial Results

Cue Biopharma reported encouraging Phase 1 clinical trial results for CUE-101 and CUE-102, along with a financial update for the third quarter of 2024, highlighting increased collaboration revenue and reduced operating expenses.

Summary

• Cue Biopharma announced its third quarter 2024 financial results and provided an update on its clinical programs.
• The company presented updated positive data from Phase 1 trials of CUE-101 and CUE-102 at the Society for Immunotherapy of Cancers 39th Annual Meeting.
• CUE-101, in combination with pembrolizumab, showed a 46% objective response rate, a 91.3% 12-month overall survival, and a median overall survival of 21.8 months in first-line HPV+ R/M HNSCC patients.
• CUE-102 monotherapy demonstrated a 67% disease control rate in late-stage pancreatic cancer patients, including an unconfirmed partial response with a 40% decrease in tumor burden.
• Collaboration revenue increased by $1.2 million to $3.3 million for the quarter ended September 30, 2024, compared to the same period in 2023.
• Research and development expenses decreased by $0.5 million to $9.4 million for the quarter, and general and administrative expenses decreased by $0.7 million to $2.9 million.
• The company's cash and cash equivalents were approximately $32.4 million as of September 30, 2024, and are expected to fund operations into the fourth quarter of 2025.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial data and improved financial metrics, suggesting a positive outlook for the company. However, the company is still loss-making and has risks associated with its development programs.

Positives

• The Phase 1 trial data for CUE-101 and CUE-102 showed promising results, indicating potential for new cancer treatments.
• The company's collaboration revenue increased, demonstrating successful partnerships.
• Operating expenses decreased, showing improved cost management.
• The company has sufficient cash to fund operations into the fourth quarter of 2025.
• The company appointed a new Chief Business Officer, Lucinda Warren, bringing industry expertise.

Negatives

• The company experienced a net loss of $8.66 million for the third quarter of 2024.
• Cash and cash equivalents decreased from $48.5 million at the end of 2023 to $32.4 million as of September 30, 2024.

Risks

• The company has a limited operating history and a history of losses.
• There are risks associated with research and development efforts, including potential setbacks in clinical trials.
• The company's ability to secure FDA approvals for its product candidates is not guaranteed.
• The company relies on collaborators and other business partners, which introduces risk.
• The company needs to obtain adequate financing to fund its business operations in the future.
• There are competitive factors and general economic conditions that could impact the company.

Future Outlook

The company expects its current cash and cash equivalents to fund operations into the fourth quarter of 2025 and is focused on advancing its preclinical autoimmune programs towards drug candidate selection.

Management Comments

• Daniel Passeri, chief executive officer of Cue Biopharma, stated that they are very pleased with the validating updated clinical data from their Phase 1 trials for both CUE-101 and CUE-102.
• Management believes the maturing data further supports and strengthens their competitive differentiation and positioning for selective modulation of disease-specific T cells.
• Management believes the CUE-100 series represents the potential of establishing a new standard of care for cancer patients.
• Management is also pleased with the continued progress of their preclinical autoimmune programs.

Industry Context

The positive clinical trial results for CUE-101 and CUE-102 position Cue Biopharma as a potential competitor in the immuno-oncology space, particularly in the treatment of HPV+ R/M HNSCC and pancreatic cancer. The company's focus on selective T-cell modulation aligns with the broader industry trend towards targeted therapies.

Comparison to Industry Standards

• The 46% objective response rate for CUE-101 in combination with pembrolizumab is competitive with other checkpoint inhibitor combinations in first-line HPV+ R/M HNSCC.
• The 91.3% 12-month overall survival rate for CUE-101 in combination with pembrolizumab is higher than historical studies with pembrolizumab alone.
• The median overall survival of 21.8 months for CUE-101 in combination with pembrolizumab is a positive result compared to other treatments in this patient population.
• The 67% disease control rate for CUE-102 in late-stage pancreatic cancer is encouraging, as this is a difficult-to-treat cancer with limited treatment options.
• Companies like Merck (Keytruda) and Bristol Myers Squibb (Opdivo) are major players in the checkpoint inhibitor space, and Cue Biopharma's results suggest they could be a potential competitor in the future.

Management Changes

Stakeholder Impact

• Shareholders may view the positive clinical trial data and improved financial metrics favorably.
• Employees may be encouraged by the company's progress and future prospects.
• Patients may benefit from the development of new cancer treatments.
• Collaborators may be encouraged by the company's progress and potential for future partnerships.

Next Steps

• The company will continue to advance its preclinical autoimmune programs towards drug candidate selection.
• The company will continue to monitor and report on the progress of its clinical trials.

Key Dates

Keywords

Cue Biopharma, CUE-101, CUE-102, Immuno-STAT, Cancer Therapy, Immunotherapy, Clinical Trials, Biopharmaceutical, Financial Results, T cells